NCT05475821View on ClinicalTrials.gov

Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 25, 2022

Primary Completion Date

September 26, 2022

Study Completion Date

September 26, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

ABBV-990

Oral Tablet

DRUG

Placebo for ABBV-990

Oral Tablet

Trial Locations (1)

60030

Acpru /Id# 247995, Grayslake

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY